DJIA 17,730.11 -27.80 -0.16%
NASDAQ 5,009.21 -3.91 -0.08%
S&P 500 2,076.78 -0.64 -0.03%
market minute promo

Celgene (NASDAQ: CELG)

119.52 1.30 (1.10%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CELG $119.52 1.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $118.56
Previous Close $118.22
Daily Range $118.52 - $119.89
52-Week Range $82.90 - $129.06
Market Cap $94.8B
P/E Ratio 40.49
Dividend (Yield) $0.00 (0.0%)
Volume 4,287,863
Average Daily Volume 3,963,659
Current FY EPS $4.07

Sector

Healthcare

Industry

Drug Makers

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website: http://www.celgene.com/

News & Commentary Rss Feed

3 Common Pitfalls Biotech Investors Need to Learn to Avoid

Here is a look at three common mistakes investors make when buying biotech stocks.

Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!

Celgene Goes For Broke

The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Pre

The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases

3 Health Care Stocks On The Rise

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

IBB, CELG, AMGN, REGN: Large Inflows Detected at ETF

What Is Beyond Vision-Loss Blockbuster For Regeneron?

Celgene: The Juno Therapeutics Deal Is Worth The Premium

Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Ana

Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog

Stock Market News for July 01, 2015 - Market News

See More CELG News...

CELG's Top Competitors

CELG $119.52 (1.10%)
Current stock: CELG
AMGN $153.26 (-1.12%)
Current stock: AMGN
GILD $115.04 (-0.84%)
Current stock: GILD
$0.00 (0.00%)
Current stock: